Xiao Fan (pseudonym), the first child with neuroblastoma to be treated with GD2 monoclonal antibodies in China, completed the first course of treatment at Hainan Women and Children's Medical Center Lecheng Branch from Nov 13 to 23, 2020.

Dinutuximab beta is a GD2 monoclonal antibody developed by EUSA Pharma. GD2 is a ganglioside highly expressed on the surface of neuroblastoma. After binding to the GD2 antibody, immune cells such as macrophages and granulocytes can recognize tumor cells and initiate attacks.